Abstract Library

#4283 Long-term efficacy and safety of peptide receptor radionuclide therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumour: Japanese phase I and phase I/II extension study

Introduction: PRRT with 177Lu-DOTATATE has been approved in Japan according to Japanese phase I and Phase I/II clinical trials. Primary end point of these clinical studies was safety and response rate, therefore, long-term efficacy and safety of PRRT for Japanese patients with NET are uncertain.

Conference:

Presenting Author: Ichikawa Y

Authors: Kobayashi N, Ono H, Okubo N, Akahoshi K, Kudo A,

Keywords: Neuroendocrine tumour, Peptide receptor radionuclide therapy, Japanese patients,

#4012 14 years of the Czech Neuroendocrine Tumors Registry

Introduction: Czech Cooperative Group for NETs was established on 22 April 2008. It continues with the practices of the Czech Carcinoid Group founded 1998. The Czech Neuroendocrine Registry was started in 2009 as a platform that should facilitate the data based on communication among various specialists treating NETs.

Conference:

Presenting Author:

Authors: Barkmanova J, Sedlackova E,

Keywords: neuroendocrine registry, population-based system, neuroendocrine tumor (NET),

#3263 Prognostic factors in curative resected locoregional small intestine neuroendocrine neoplasms

Introduction: Small intestinal neuroendocrine neoplasms (SI-NEN) are rare and only about 40% of patients are diagnosed without distant metastases.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Maurer E

Authors: Bartsch D, Maurer E, Evers M, Ramaswamy A, Rinke A,

Keywords: SI-NEN, stage 3, surgery,

#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors

Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Li Y, Tan H, Jie C, Jie L, Pan Z,

Keywords: clinicopathological features, prognostic analysis, well-differentiated gastric neuroendocrine tumors, grade, type,

#2211 Clinicopathologic Characteristics of Chinese Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study

Introduction: he rare incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has contributed to a paucity of large epidemiologic studies of patients with this condition, especially in China.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yu P, Chi Y, Shi S, Chen Y, Jiang L,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, clinicopathological characteristics, immunohistochemical staining,